No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Overcapitalization in AI depresses future returns
Massive capital inflows into AI lower future venture returns, while underfunded sectors like biotech secondary spinouts present superior return potential.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day — no card required.